{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:13:56Z","timestamp":1779909236657,"version":"3.53.1"},"reference-count":31,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Despite the introduction of targeted therapies such as Nivolumab, survival outcomes for patients with esophageal adenocarcinoma remain poor. During tumorigenesis, some tumors develop auxotrophy by downregulation of Argininosuccinate Synthetase-1 (ASS1), making them reliant on external arginine supply and thus potentially susceptible to arginine deprivation therapy. Arginine deprivation therapy with agents such as pegargiminase has shown improved survival in patients with pleural mesothelioma exhibiting ASS1 loss in tumor cells. Therefore, we investigated the prevalence of ASS1 loss in esophageal adenocarcinoma. Methods: First, we compared the staining patterns of three antibodies for ASS1 with RNA in situ Scope analysis results to identify the most reliable antibody for ASS1 immunohistochemical staining in esophageal adenocarcinoma. Subsequently, we performed ASS1 immunohistochemical staining on samples from 97 patients who underwent curative resection. The staining results were classified into three categories based on expression levels: negative, low-positive, and positive. Results: Among all included patients, 6.2% exhibited an ASS1 loss, and 6.2% showed low ASS1 expression. Notably, patients with an ASS1 loss did not demonstrate a response to neoadjuvant therapy. Patients with ASS1 loss or low expression were significantly younger. Conclusions: Our findings indicate that approximately 12.4% of patients with esophageal adenocarcinoma may be eligible and could potentially benefit from arginine deprivation therapy. This underscores the urgent need for clinical trials evaluating the efficacy of pegargiminase in this patient population. Additionally, incorporating ASS1 immunohistochemical staining into pre-neoadjuvant biopsy assessments should be considered to optimize neoadjuvant treatment strategies and advance the implementation of personalized cancer therapy.<\/jats:p>","DOI":"10.3390\/cancers17223624","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:57:41Z","timestamp":1762851461000},"page":"3624","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Loss of Argininosuccinate Synthetase-1 (ASS1) Occurs in Esophageal Adenocarcinoma and Represents a Promising Biomarker for Therapy with Pegargiminase"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7133-3538","authenticated-orcid":false,"given":"Karl","family":"Knipper","sequence":"first","affiliation":[{"name":"Department of General, Visceral, Thoracic and Transplantation Surgery, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4125-6048","authenticated-orcid":false,"given":"Su Ir","family":"Lyu","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tzitzili","sequence":"additional","affiliation":[{"name":"Department of General, Visceral, Thoracic and Transplantation Surgery, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Michele","family":"Spielmann","sequence":"additional","affiliation":[{"name":"Department of General, Visceral, Thoracic and Transplantation Surgery, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-8181","authenticated-orcid":false,"given":"Christiane J.","family":"Bruns","sequence":"additional","affiliation":[{"name":"Department of General, Visceral, Thoracic and Transplantation Surgery, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-3675","authenticated-orcid":false,"given":"Thomas","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of General, Visceral, Thoracic and Transplantation Surgery, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix C.","family":"Popp","sequence":"additional","affiliation":[{"name":"Department of General, Visceral, Thoracic and Transplantation Surgery, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3537-6011","authenticated-orcid":false,"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1046\/j.1432-1033.2003.03559.x","article-title":"Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle","volume":"270","author":"Husson","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sun, N., and Zhao, X. (2022). Argininosuccinate synthase 1, arginine deprivation therapy and cancer management. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.935553"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/abbs\/gmz005","article-title":"Argininosuccinate synthase 1 suppresses cancer cell invasion by inhibiting STAT3 pathway in hepatocellular carcinoma","volume":"51","author":"Tao","year":"2019","journal-title":"Acta Biochim. Biophys Sin"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-12-2641","article-title":"ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: Aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance","volume":"19","author":"Huang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41419-024-06672-z","article-title":"ASS1 inhibits triple-negative breast cancer by regulating PHGDH stability and de novo serine synthesis","volume":"15","author":"Luo","year":"2024","journal-title":"Cell. Death Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40170-021-00264-7","article-title":"The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer","volume":"9","author":"Giatromanolaki","year":"2021","journal-title":"Cancer Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s13277-013-1020-8","article-title":"Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: Negative prognostic impact and therapeutic relevance","volume":"35","author":"Lan","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.canlet.2020.12.041","article-title":"Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination","volume":"502","author":"Zhang","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_11","first-page":"5443","article-title":"Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo","volume":"62","author":"Ensor","year":"2002","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Brierley, J.D.E. (2021). TNM Atlas, Wiley-Blackwell. [7th ed.].","DOI":"10.1002\/9781119263906"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/01.sla.0000186170.38348.7b","article-title":"Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification","volume":"242","author":"Schneider","year":"2005","journal-title":"Ann. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3892\/ol.2024.14628","article-title":"Hexokinase 2 as an independent risk factor for worse patient survival in esophageal adenocarcinoma and as a potential therapeutic target protein: A retrospective, single--center cohort study","volume":"28","author":"Lyu","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","article-title":"RNAscope: A novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues","volume":"14","author":"Wang","year":"2012","journal-title":"J. Mol. Diagn."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1943253","DOI":"10.1080\/2162402X.2021.1943253","article-title":"Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers","volume":"10","author":"Chang","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1002\/cam4.4196","article-title":"Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer","volume":"10","author":"Szlosarek","year":"2021","journal-title":"Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbrc.2022.08.045","article-title":"ASS1 regulates immune microenvironment via CXCL8 signaling in ovarian cancer","volume":"631","author":"Feng","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cllc.2020.07.012","article-title":"Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer","volume":"21","author":"Hall","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13046-021-01912-y","article-title":"Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK\/eIF2\u03b1\/ATF4\/CHOP axis in hepatocellular carcinoma","volume":"40","author":"Kim","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.21037\/tcr-21-794","article-title":"Abnormal arginine metabolism is associated with prognosis in patients of gastric cancer","volume":"10","author":"Shi","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ding, Q., Li, R., Wang, Q., Yu, L., and Zi, F. (2023). A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1049147"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.21037\/jtd.2016.09.61","article-title":"Clinicopathological features and prognosis of patients <45 years old with esophageal adenocarcinoma comparing to other age groups","volume":"8","author":"Yang","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/s13287-025-04622-w","article-title":"The role of ASS1 in mouse embryonic stem cell differentiation into mesendoderm lineages","volume":"16","author":"Zhao","year":"2025","journal-title":"Stem. Cell. Res. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature15529","article-title":"Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis","volume":"527","author":"Rabinovich","year":"2015","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s42255-024-01060-5","article-title":"ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response","volume":"6","author":"Lim","year":"2024","journal-title":"Nat. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Knipper, K., Damanakis, A.I., Zhao, Y., Bruns, C.J., Schmidt, T., Popp, F.C., Quaas, A., Lyu, S.I., and Pancalyze Study Group (2023). Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. Cancers, 15.","DOI":"10.3390\/cancers15072049"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3624\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:11:43Z","timestamp":1762852303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":31,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17223624"],"URL":"https:\/\/doi.org\/10.3390\/cancers17223624","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}